US Bancorp DE Has $707,000 Stock Holdings in Masimo Co. (NASDAQ:MASI)

US Bancorp DE cut its position in shares of Masimo Co. (NASDAQ:MASI) by 2.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,280 shares of the medical equipment provider’s stock after selling 90 shares during the period. US Bancorp DE’s holdings in Masimo were worth $707,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. UMB Bank n.a. lifted its stake in shares of Masimo by 180.9% in the fourth quarter. UMB Bank n.a. now owns 191 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 123 shares during the last quarter. Trust Co. of Vermont bought a new stake in Masimo during the fourth quarter valued at about $33,000. Blue Trust Inc. grew its position in shares of Masimo by 56.3% in the fourth quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 71 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Masimo by 136.5% during the 4th quarter. GAMMA Investing LLC now owns 466 shares of the medical equipment provider’s stock worth $77,000 after purchasing an additional 269 shares during the last quarter. Finally, Harvest Fund Management Co. Ltd bought a new stake in Masimo during the 3rd quarter valued at approximately $118,000. 85.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MASI. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research report on Friday, November 22nd. Needham & Company LLC reiterated a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company increased their price objective on shares of Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Piper Sandler lifted their target price on shares of Masimo from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Finally, Raymond James increased their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an “outperform” rating in a research report on Friday, December 27th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $194.80.

Masimo Stock Performance

Shares of NASDAQ:MASI opened at $165.45 on Tuesday. The company has a market capitalization of $8.93 billion, a price-to-earnings ratio of 114.10 and a beta of 1.04. The firm’s 50 day simple moving average is $174.89 and its 200 day simple moving average is $156.55. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. Masimo Co. has a fifty-two week low of $101.61 and a fifty-two week high of $194.88.

Masimo (NASDAQ:MASI) last announced its quarterly earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company had revenue of $600.70 million during the quarter, compared to the consensus estimate of $593.35 million. As a group, sell-side analysts forecast that Masimo Co. will post 4.1 earnings per share for the current year.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.